Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

View:
Post by flad101 on Jan 13, 2021 11:36am

Awesome

This is great.  Almost time to short this again. Go medi.  Go up a bit more.
Comment by Lemoyne on Jan 13, 2021 11:50am
Lol, you have good timing. I bet some of your peers that got in below .60 are getting worried right about now.
Comment by Hound2010 on Jan 13, 2021 12:12pm
glad the great..go ahead short it and get killed by q4 earnings
Comment by Lemoyne on Jan 13, 2021 12:18pm
depends what the stock price is at that point. Don't forget OGI earnings that happened this week. doesn't matter if your revenues grow if your other metrics are sh*t. The stock pays for it by imploding
Comment by Righttothetop on Jan 13, 2021 12:42pm
Q4 will not crush expectations....if anything, they will hopefully at least show stabilization.  But what's happening to LABS now is people seeing value (undervalue really) relative to other like peers.  There's no reason why VLNS (as good as it is) is valued so much more... So people are bargain hunting with TFSA money and in other ways, looking to play the fladdie short game.  ...more  
Comment by Lemoyne on Jan 14, 2021 9:06am
Taken a position yet?
Comment by Righttothetop on Jan 14, 2021 9:51am
Given the entire sector is also blowing up...I think there's a US market opening up aspect to all of this excitment too. Again, have to say, a welcome change.....hopefully international news will also be positive.
Comment by Lemoyne on Jan 14, 2021 10:03am
I think private brand sales are really encouraging, with sqdc eventually piling on, this has significant potential to continue growing over the whole of 2021 (retail + new provinces ramping up). internationally, i'm optimistic this will also increase in Q4 but most importantly, the announcement of stada shipment could number in 10's of thousands of units, maybe reaching 100k + IF they ...more  
Comment by Righttothetop on Jan 14, 2021 12:12pm
I think most rational people who know and follow this stock realized that it had potential even beyond the recent miscues. Hopefully they can provide hard proof that they turned the ship around cause at these levels, LABS is a steal if they did.... A nice CEO announcement would do wonders as well.  Positive directions probably make it much easier to attract some high prized talent certainly ...more  
Comment by flad101 on Jan 14, 2021 12:23pm
No position yet.  But soon I will. I figure she has a bit more of a bump to go.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities